title: Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia. [corrected].
abstract: A 62-year-old woman with chronic lymphocytic leukemia [corrected] (CLL) who initially presented with lymphocytosis and 13q deletion in 1996 now presents to the clinic for recommendations regarding relapsed disease. The patient has received multiple prior therapies, including single-agent fludarabine, fludarabine and rituximab, and bendamustine and rituximab. She now has recurrent lymphocytosis with a WBC count that has increased from 13,000 2 months ago to 115,000 today and a platelet count of 55,000 but no lymphadenopathy. In addition, your evaluation finds that she has acquired a 17p deletion.
authors.affiliation: Harvard Medical School, Boston, MA, USA. jarnason@bidmc.harvard.edu
authors.forename: Jon E
authors.initials: JE
authors.lastname: Arnason
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Brown
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology* / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000494:pharmacology* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab